RESUMEN
The pharmaco-toxicological profile of duloxetine, a novel SNRI antidepressant, is still not completely known; in particular, intoxication cases have been scarcely studied. Here a duloxetine overdose case, in combination with other antidepressants and benzodiazepines, is reported and the chemical-clinical correlations discussed; this is probably the first detailed report of such a case. The patient referred to have ingested nine tablets of Cymbalta (more than 500 mg of duloxetine) and high amounts of four other drugs (venlafaxine, trazodone, sertraline and clonazepam). The patient was dozy and confused and some electrolyte imbalances were found. After gastrolavage, toxicological analyses revealed high plasma levels of duloxetine (384 ng/ml) and low levels of the other supposedly involved drugs. The overdose resulted to be not fatal and the outcome was relatively benign, also thanks to the fast emergency assistance. This case suggests that clinicians should be alerted to the possibility of toxic effects caused by simultaneous overdoses of duloxetine and other antidepressants and that caution should be used when prescribing more than one of these drugs to patients at risk of suicide.
Asunto(s)
Antidepresivos/toxicidad , Trastorno Depresivo Mayor/tratamiento farmacológico , Sobredosis de Droga/diagnóstico , Intento de Suicidio/psicología , Tiofenos/toxicidad , Afecto/efectos de los fármacos , Anciano , Antidepresivos/farmacocinética , Antidepresivos/uso terapéutico , Cromatografía Líquida de Alta Presión , Confusión/sangre , Confusión/inducido químicamente , Trastorno Depresivo Mayor/sangre , Trastorno Depresivo Mayor/psicología , Interacciones Farmacológicas , Sobredosis de Droga/sangre , Sobredosis de Droga/psicología , Sobredosis de Droga/terapia , Quimioterapia Combinada , Clorhidrato de Duloxetina , Femenino , Lavado Gástrico , Humanos , Acontecimientos que Cambian la Vida , Tasa de Depuración Metabólica/fisiología , Tiofenos/farmacocinética , Tiofenos/uso terapéuticoRESUMEN
The present study investigated the effects of second generation antipsychotics (SGA) on the metabolism of 15 antipsychotic-naïve outpatients. Evaluations were performed at baseline and after 1 month of treatment. A significant increase in mean body mass index (BMI) and mean waist circumference was observed. These results suggest the importance of monitoring patients from the first few weeks of antipsychotic treatment.
Asunto(s)
Síndrome Metabólico/epidemiología , Obesidad/epidemiología , Esquizofrenia/tratamiento farmacológico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Glucemia/metabolismo , Índice de Masa Corporal , Femenino , Humanos , Masculino , Síndrome Metabólico/sangre , Persona de Mediana Edad , Estudios ProspectivosRESUMEN
BACKGROUND: Second generation antipsychotics (SGA) have demonstrated several advantages over first generation antipsychotics (FGA) in terms of positive, negative, cognitive, and affective symptoms and a lower propensity for extrapyramidal side effects. Despite these undeniable advantages, SGA have been associated with causing and exacerbating metabolic disorders, such as obesity, diabetes, and hyperlipidemia. This cross sectional study aimed to evaluate the metabolic risk factor profile associated with use of SGAs in comparison with non -treated control patients. METHODS: The study was carried out at a Community Mental Health Centre (CMHC) in Bologna. The study subjects were outpatients with serious mental disorders treated with SGA (clozapine, olanzapine, risperidone, quetiapine). A sample of adult men and women suffering from idiopathic hyperhydrosis, without psychiatric history or antipsychotic treatment, were randomly selected from outpatients of the Department of Neurology in Bologna as a reference group. We investigated differences among the treatment and reference groups for glycaemia, cholesterolaemia and triglyceridaemia levels. RESULTS: The study sample was composed of 76 patients, 38 males and 38 females. The reference group was composed of 36 subjects, 19 females and 17 males. All patients treated with SGAs had higher mean glycaemia and triglyceridaemia and a significantly higher risk of receiving a diagnosis of hyperglycaemia and hypertriglyceridaemia than the reference group. We did not find any differences in mean glycaemia or mean triglyceridaemia levels among treatment groups. Patients with clozapine had a significantly higher mean BMI value and rate of obesity than patients treated with other SGAs. CONCLUSION: The rate of obesity and metabolic disorders observed in this study were higher than the prevalence in the control group and similar to that previously reported in psychiatric samples; these findings imply per se that more attention should be paid to the metabolic condition of psychiatric patients. In line with the International Consensus Conferences we recommend that monitoring of weight, fasting plasma glucose, cholesterol and triglyceride levels be obtained in routine clinical practice with all antipsychotics.